NCT04588480View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

November 25, 2021

Study Completion Date

November 25, 2021

Conditions
SARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

BNT162b2

BNT162b2 (intramuscular injection)

OTHER

Placebo

Placebo (intramuscular injection)

Trial Locations (2)

130-0004

SOUSEIKAI Sumida Hospital, Sumida-ku

812-0025

SOUSEIKAI PS Clinic, Fukuoka

Sponsors

Lead Sponsor

BioNTech SE

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

BioNTech SE

INDUSTRY